Reply
Honored Social Butterfly

Vaccine Development Threatened as COVID-19 Infections Decline

Vaccine Development Threatened as COVID-19 Infections Decline

 

BY:  Stacy Lennox

 

A COVID-19 vaccine developed by Oxford University has generated significant interest. Both the United States and the United Kingdom have ordered large numbers of doses in anticipation of successful human trials. The development cycle for this particular vaccine was shortened because it has already been tested in primates with good results.

 

President Trump announced Operation Warp Speed, which is aimed at expediting the development and approval of an effective vaccine. This includes upending the traditional production of them. Top vaccine candidates will be manufactured in advance of demonstrating effectiveness so they will be available more quickly.

 

The Oxford vaccine is one of these candidates and AstraZeneca has struck a deal to produce the vaccine in advance of the conclusion of the human trial. This effort has been backed by $1 billion in U.S. taxpayer money. The goal is to produce 300 million doses by November of 2020.

Not Enough COVID-19

 

However, Oxford researchers are now warning of an obstacle in the trial process. As new cases of COVID-19 are declining, they worry the data will not meet the hurdles to prove effectiveness. They are now placing the odds of a successful trial at 50%. Professor Adrian Hill is sounding the alarm:

 

The stakes could hardly be higher. If proven effective, the ZD1222 vaccine would allow people to leave their homes and go back to work, and the shattered global economy to rebuild. But Hill, director of the university’s Jenner Institute, revealed his team now faced a major problem, throwing the September deadline into doubt.

 

“It is a race, yes. But it’s not a race against the other guys. It’s a race against the virus disappearing, and against time,” he said. “At the moment, there’s a 50 per cent chance that we get no result at all.”

The professor went on to explain that the trial has recruited 10,000 individuals to take the vaccine. He would expect fewer than 50 to contract COVID-19. If fewer than 20 do, Hill says the results will be useless, putting the trial in jeopardy.

 

“We’re in the bizarre position of wanting COVID to stay, at least for a little while. But cases are declining.”

Bizarre no doubt, given we were all assured cases would explode as lockdown restrictions were lifted.

The Vaccine Conundrum

This also places residents in some areas of the United States in quite a conundrum. State and local leaders like Mayor Eric Garcetti of Los Angeles and Governor Tom Wolfe of Pennsylvania have said that their citizens cannot return to normal until we have an effective vaccine.

 

However, according to Professor Hill, we can’t have an effective vaccine unless the virus is spreading at a rate sufficient to infect a statistically significant portion of the test group. It appears we have slowed the spread to such a degree it may deprive us of the vaccine so many are desperately relying on.

Protect the Vulnerable

This is just another reason to loosen lockdown restrictions. In order to test vaccines, the virus needs to circulate. In order for it to circulate people need to be moving around in public. Clearly to get to this point quickly and safely a few things need to happen. This approach should be bolstered by the CDC’s mortality data revisions.

 

As our health experts have often said, we need to learn to do two things at once. The data shows COVID-19 is most severe in the elderly with pre-existing conditions. Data shows the experience in nursing homes and assisted living facilities is particularly devastating. The public health system must figure out how to scrupulously protect these residents through aggressive sentinel testing and protective measures.

 

Let COVID-19 Circulate

 

The virus is least likely to be severe and result in death for people under 50. This is the vast majority of the school and working-age population. Let these people get back to their normal lives taking care to advise those with pre-existing conditions associated with severe or fatal outcomes on how they can protect themselves.

 

Doctors and clinicians should focus their efforts on information sharing and educating the public on symptoms and treatments aimed at mitigating the most serious disease in the under-50 cohort. There is increasing evidence this is due to an immune system overreaction called a cytokine storm.

 

Treatment protocols for this condition, such as the one developed by the ICU team at Cedars Sinai Providence, should be widely shared and refined. The FDA should be giving Emergency Use Authorizations for the drugs involved in this treatment as well as the antivirals and other drugs it has been applied to.

 

Finally, silent hypoxia, or lack of oxygen in the blood, seems to be an early indicator of severe disease in COVID-19. Patients who test positive for the virus should be encouraged to purchase or be loaned a pulse oximeter to continuously monitor this level and given instructions on what level indicates they should seek medical attention immediately.

 

The idea of herd immunity appears harder to obtain than originally thought given the original infection rate or R0 that was calculated. Sweden, which chose to pursue this model, only has an antibody rate of 7.3% in Stockholm as of the end of April. This is well below the expectation of 60% forecasted originally. This information also presents a hurdle to vaccine development. It is spreading more slowly than assumed.

 

Allowing the virus to circulate among the population least likely to suffer fatal outcomes is critical to the successful development of a vaccine. A successful vaccine, should one be developed, will allow our high-risk population to confidently return to a normal life. If we don’t move to do this quickly and safely, we only delay the development of the best preventative tool we have.

 

 

 

VIMTSTL
Honored Social Butterfly

This from the original post is where the author of the article gets it right by quoting the actual researchers at Oxford that are doing the work:

 

++++++++++++++++++

 

However, Oxford researchers are now warning of an obstacle in the trial process. As new cases of COVID-19 are declining, they worry the data will not meet the hurdles to prove effectiveness. They are now placing the odds of a successful trial at 50%. Professor Adrian Hill is sounding the alarm:

 

The stakes could hardly be higher. If proven effective, the ZD1222 vaccine would allow people to leave their homes and go back to work, and the shattered global economy to rebuild. But Hill, director of the university’s Jenner Institute, revealed his team now faced a major problem, throwing the September deadline into doubt.

 

“It is a race, yes. But it’s not a race against the other guys. It’s a race against the virus disappearing, and against time,” he said. “At the moment, there’s a 50 per cent chance that we get no result at all.”

The professor went on to explain that the trial has recruited 10,000 individuals to take the vaccine. He would expect fewer than 50 to contract COVID-19. If fewer than 20 do, Hill says the results will be useless, putting the trial in jeopardy.

 

“We’re in the bizarre position of wanting COVID to stay, at least for a little while. But cases are declining.”

 

 

+++++++++++++++++++++++++++

 

Investigative journalism at its best.  A major part of this story is bittersweet in that COVID is declining...

 

 

 

 

 

 

VIMTSTL
Honored Social Butterfly


@jimc91 wrote:

This from the original post is where the author of the article gets it right by quoting the actual researchers at Oxford that are doing the work:

 

++++++++++++++++++

 

However, Oxford researchers are now warning of an obstacle in the trial process. As new cases of COVID-19 are declining, they worry the data will not meet the hurdles to prove effectiveness. They are now placing the odds of a successful trial at 50%. Professor Adrian Hill is sounding the alarm:

 

The stakes could hardly be higher. If proven effective, the ZD1222 vaccine would allow people to leave their homes and go back to work, and the shattered global economy to rebuild. But Hill, director of the university’s Jenner Institute, revealed his team now faced a major problem, throwing the September deadline into doubt.

 

“It is a race, yes. But it’s not a race against the other guys. It’s a race against the virus disappearing, and against time,” he said. “At the moment, there’s a 50 per cent chance that we get no result at all.”

The professor went on to explain that the trial has recruited 10,000 individuals to take the vaccine. He would expect fewer than 50 to contract COVID-19. If fewer than 20 do, Hill says the results will be useless, putting the trial in jeopardy.

 

“We’re in the bizarre position of wanting COVID to stay, at least for a little while. But cases are declining.”

 

 

+++++++++++++++++++++++++++

 

Investigative journalism at its best.  A major part of this story is bittersweet in that COVID is declining...

 

 

 

 

 

 


Here you see the attempt to bring back the subject in a different light.  The real thing the good Proff. is telling us is that they have had some setbacks and could be late so their adv. release date could not be good now.

Every new vaccine goes through the same trial process. Many of the vaccines are used on diseases which have far fewer cases than this virus. Did you ever hear an appeal to spread the disease to more people so we could test the vaccine. Vaccine approval depends on test group which are put together by the developer not spreading the disease.     

Only in far right fantasy land is this would this be good investigative journalism, but in Trump land it is tops.    

0 Kudos
425 Views
1
Report
Trusted Social Butterfly

"Only in far right fantasy land is this would this be good investigative journalism, but in Trump land it is tops."

 

Well said John258.

 

 

0 Kudos
417 Views
0
Report
Honored Social Butterfly

All should read the support article very carefully. It states it has already been tested in primates. All vaccines are tested that way and a number of the current ones have past this stage. That is a tip off that the author does not really know much about what they are writing about.  Later on in the article the writer tells us that one of the developers says the virus is not spreading fast enough to be able to test it, so we should open everything up so more people will get the virus so the vaccine can be tested on a lot of people. In other words we need more people to die and get sick. Well when they do the large tests on humans it is on a large control group and they select that group from volunteers who do not have the virus. They give the group the vaccine and virus then monitor them.  We have all seen some of these volunteers on TV already. The final test is when they use the vaccine on regular people and they will monitor what happens. There are plenty of people.

What we see here is a far right article written to justify the mess Trump has created and as usual if followed people die. The answer is to get rid of Trump in Nov. and then we will be able to get rid of the virus.

Honored Social Butterfly

And let’s say that some may be really skeptical about a vaccine being available so quickly, especially when it’s being advanced by trump and his administration. 
Sounds like there is some backtracking going on. Most medical experts say that even a timetable of a year to year and a half are extremely optimistic...let alone having a 6-7 month availability of a vaccine. 
Wouldn’t more tests help to deal with who has the virus and who doesn’t? 
Remember all the testing that trump promised...and now declines to support!

0 Kudos
467 Views
1
Report
Esteemed Social Butterfly

Not enough infections in a test group of 10000 who were recruited, huh?  Maybe they should expand the test group.  Seeking volunteers to get infected with COVID19.

 

This is one test program taking place in the U.K. where the number of infections has declined.  Globally, there are currently 224 vaccine programs underway. 

 

Vaccine development is not threatened.  It might be for one program taking place in a country with a significant drop in infections, but no need to panic yet.

cancel
Showing results for 
Show  only  | Search instead for 
Did you mean: 
Users
Announcements

Does AARP donate to political parties or endorse candidates?

AARP is strictly non-partisan and always has been. We never endorse or donate to candidates, political parties or political action committees.

Learn more.

AARP Members Only Games

Play members only games, like FIll Ins, Lumeno, 2048 and a collaborative, multiplayer Let's Crossword.

Play Now
AARP Members Only Games Logos
AARP Rewards

Solve Crosswords. Earn Rewards. Activate AARP Rewards to earn points for games, quizzes and videos. Redeem for deals and discounts.

Get started with AARP Rewards now!
/html/assets/Rewards-program-badge-355x224.png